351 related articles for article (PubMed ID: 29291023)
1. Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L; Daver N
Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
4. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Jonas BA; Hou JZ; Roboz GJ; Alvares CL; Jeyakumar D; Edwards JR; Erba HP; Kelly RJ; Röllig C; Fiedler W; Brackman D; Siddani SR; Chyla B; Hilger-Rolfe J; Watts JM
Hematol Oncol; 2023 Oct; 41(4):743-752. PubMed ID: 37086447
[TBL] [Abstract][Full Text] [Related]
8. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
9. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
11. A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.
Sim KM; Kim SY; Hwang S; Park S; Lee BR; Nam K; Oh S; Kim I
Chem Biol Interact; 2023 Sep; 382():110554. PubMed ID: 37271215
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
13. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia
Schwartz J; Niu X; Walton E; Hurley L; Lin H; Edwards H; Taub JW; Wang Z; Ge Y
Am J Transl Res; 2016; 8(9):3893-3902. PubMed ID: 27725868
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
17. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
19. Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia.
Zhou FJ; Zeng CX; Kuang W; Cheng C; Liu HC; Yan XY; Chen XP; Zhou G; Cao S
J Cancer; 2021; 12(22):6727-6739. PubMed ID: 34659562
[No Abstract] [Full Text] [Related]
20. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]